| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
28,040,000 |
| Market
Cap: |
64.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.08 - $3.86 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 12.1 |
| Insider 6 Months : 12.1 |
| Insider 3/6 Months : 24.4 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of immune modulator product candidates to treat solid cancers, T-cell lymphomas, autoimmune diseases and infectious diseases. Co.'s lead product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Co.'s next product candidate, CPI-818, is a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T-cell lymphomas. Co.'s third product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
597,634 |
597,634 |
597,634 |
782,524 |
| Total Buy Value |
$1,034,624 |
$1,034,624 |
$1,034,624 |
$1,196,645 |
| Total People Bought |
2 |
2 |
2 |
4 |
| Total Buy Transactions |
2 |
2 |
2 |
14 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Miller Richard A Md |
President and CEO |
• • – |
2024-05-10 |
4 |
GD |
$0.00 |
$0 |
I/I |
302,016 |
1,188,103 |
|
- |
|
| Jones William Benton |
See Remarks |
• • – |
2024-05-06 |
4 |
B |
$1.73 |
$34,624 |
D/D |
20,000 |
153,773 |
0.01 |
15% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2024-05-06 |
4 |
B |
$1.73 |
$1,000,000 |
D/D |
577,634 |
577,634 |
0.01 |
15% |
|
| Grais Linda S |
|
• • – |
2023-05-15 |
4 |
B |
$2.45 |
$24,500 |
D/D |
10,000 |
10,000 |
0.01 |
-41% |
|
| Jones William Benton |
See Remarks |
• – – |
2022-12-20 |
4 |
B |
$0.79 |
$15,800 |
D/D |
20,000 |
133,773 |
2.74 |
32% |
|
| Lea Leiv |
Chief Financial Officer |
• – – |
2022-12-14 |
4 |
B |
$0.84 |
$3,364 |
I/I |
4,000 |
133,238 |
1.91 |
28% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2022-12-14 |
4 |
B |
$0.78 |
$7,812 |
I/I |
10,000 |
1,490,119 |
2.58 |
28% |
|
| Lea Leiv |
Chief Financial Officer |
• – – |
2022-12-13 |
4 |
B |
$0.74 |
$22,275 |
I/I |
30,000 |
129,238 |
1.99 |
31% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2022-12-13 |
4 |
B |
$0.74 |
$37,015 |
I/I |
50,000 |
1,480,119 |
2.66 |
31% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2022-09-28 |
4 |
B |
$0.76 |
$19,070 |
I/I |
25,000 |
1,394,405 |
2.58 |
7% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2022-09-20 |
4 |
B |
$0.81 |
$16,253 |
I/I |
20,000 |
1,369,405 |
2.58 |
4% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2022-06-27 |
4 |
B |
$1.00 |
$4,985 |
I/I |
5,000 |
1,349,405 |
2.58 |
-22% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2022-06-24 |
4 |
B |
$1.03 |
$5,150 |
I/I |
5,000 |
1,344,405 |
2.58 |
-1% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2022-06-06 |
4 |
B |
$1.01 |
$899 |
I/I |
890 |
1,339,405 |
2.58 |
-11% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2022-06-02 |
4 |
B |
$0.97 |
$4,898 |
I/I |
5,000 |
1,338,515 |
2.58 |
-6% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2022-03-31 |
4 |
B |
$1.64 |
$24,534 |
I/I |
15,000 |
1,333,515 |
2.58 |
-47% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2022-03-17 |
4 |
B |
$1.59 |
$7,950 |
I/I |
5,000 |
1,318,515 |
2.58 |
-44% |
|
| Lea Leiv |
Chief Financial Officer |
• – – |
2022-03-17 |
4 |
B |
$1.65 |
$22,899 |
I/I |
13,878 |
99,238 |
1.99 |
-44% |
|
| Lea Leiv |
Chief Financial Officer |
• – – |
2022-03-16 |
4 |
B |
$1.54 |
$54,146 |
I/I |
35,160 |
85,360 |
1.99 |
-44% |
|
| Miller Richard A Md |
President and CEO |
• • – |
2022-03-15 |
4 |
B |
$1.47 |
$36,650 |
I/I |
25,000 |
1,313,515 |
2.66 |
-36% |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2021-10-01 |
4 |
S |
$4.96 |
$9,928,800 |
I/I |
(2,000,000) |
81,077 |
|
60% |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2021-09-30 |
4 |
S |
$5.04 |
$15,131,100 |
I/I |
(3,000,000) |
2,081,077 |
|
59% |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2021-09-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,081,077 |
|
-77% |
|
| Thompson Peter A |
Director |
– • • |
2021-09-20 |
4 |
S |
$6.09 |
$6,757,732 |
I/I |
(1,109,644) |
6,943,654 |
|
71% |
|
| Orbimed Capital Gp V Llc |
Director |
– • • |
2021-09-20 |
4 |
S |
$6.09 |
$6,757,732 |
I/I |
(1,109,644) |
6,943,654 |
|
71% |
|
115 Records found
|
|
Page 1 of 5 |
|
|
0.10 (4.57%) 
